PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates

Financial Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of +7.32% [1] - The company posted revenues of $83.33 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.35% and showing a significant increase from $58.37 million in the same quarter last year [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 57.1% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for PROCEPT BioRobotics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $96.42 million, and for the current fiscal year, it is -$1.48 on revenues of $325.4 million [7] - The trend of estimate revisions for PROCEPT BioRobotics was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]